EVGN Evogene Ltd Ord

NASDAQ
$0.31

Evogene's EPS Beat Is a Dilution Effect as Revenue Nearly Vanishes and the Story Shifts to an Early-Stage Pipeline

Evogene (EVGN) reported a third-quarter loss of $0.17 per share, beating the consensus estimate of -$0.19 by 10.5%. Earnings improved 45.2% year over year. Revenue tells a different story. It came in at just $0.14 million against a $0.37 million consensus, a 61.9% miss and a 54.8% year-over-year decline. The central tension is that the per-share improvement says more about the share count than the business. With recurring revenue now close to zero, Evogene is increasingly valued on early-stage science and a cash runway funded by dilution.

The quality of the beat deserves scrutiny. Loss from continuing operations widened to about $2.81 million from $2.36 million a year earlier, and the operating loss grew to roughly $2.98 million from $2.43 million. The per-share loss shrank anyway because the weighted share count nearly doubled, from about 8.7 million to 16.9 million. Shares outstanding reached 18.05 million at quarter-end, compared with 8.72 million at the end of 2025.

On a total basis, the company swung from net income of $5.2 million in the year-ago quarter to a $2.9 million net loss. That comparison is distorted by income recognized on the 2025 sale of Lavie Bio assets and MicroBoost AI for Ag to ICL. Sequentially, though, the picture also worsened: the net loss widened from about $1.8 million in the second quarter.

Costs moved in mixed directions:

  • R&D rose to $1.5 million from $1.1 million. Management attributed this mainly to grant credits that reduced the prior-year figure and to currency effects.
  • G&A held flat only because roughly $0.3 million of non-recurring legal and governance costs tied to the dissident shareholder contest offset underlying savings.
  • Equity attributable to Evogene shareholders was negative $3.7 million at quarter-end.

The revenue collapse has a clear cause. The Bayer license and collaboration ended in May 2026, and Casterra's 2025 seed sales have not recurred. Nine-month revenue fell to about $0.8 million from $3.2 million.

The operational momentum of the first half has also stalled. After four collaborations were signed in the first half, bringing the total to six, no new agreements were announced this quarter. The CEO deferred updates on the partnered pipeline to the next call. The tone shifted from the expansive language of the second-quarter call to a narrower, technical presentation. Only one analyst question was taken. Management also did not repeat its prior full-year cash-usage guidance of $8.5 million to $9.5 million, although nine-month usage of about $7.3 million remains consistent with that range.

The call did preserve a credible scientific narrative, and the internal programs are the real development of the quarter:

  • **Pharma program:** The internal drug discovery effort moved from generic lead optimization to a named indication, steroid-refractory acute graft-versus-host disease. Management cited novel small molecules with nanomolar potency and encouraging early ADME and toxicology data. Advisors from Dana-Farber and University Medical Center Freiburg are involved. Preclinical entry is targeted around mid-2027.
  • **AgPlenus fungicide program:** The Septoria program has progressed meaningfully since the first-quarter call. It now has two novel-mode-of-action targets, activity against SDHI-resistant strains, and up to 75% disease-severity reduction in plant tissue assays. Greenhouse and field trials are planned for 2027, and management reported early partner interest.

That Septoria program is the most plausible near-term source of a collaboration. Still, both programs remain years from meaningful revenue.

The funding picture is where bears have legitimate ammunition:

  • Third-quarter cash usage rose to about $2.4 million from roughly $2.1 million in the second quarter, including a $0.5 million D&O insurance payment.
  • Cash and deposits of $9.2 million were essentially unchanged from the prior quarter only because of about $2.4 million raised through share issuance.
  • At the current burn rate, the balance sheet funds roughly a year of operations. Further equity raises look likely before either internal program reaches the milestones management outlined.
  • The dissident shareholder situation adds a governance overhang that the company itself flags as a risk factor.

The market has treated the stock harshly since the last report. Shares opened at $0.56 after the August release and peaked at $0.61 the next day. They then slid to a 52-week low of $0.25 on November 6, less than half the post-report open and far below the 200-day moving average near $0.62. Trend readings are mixed, with price and momentum neutral while AVWAP remains negative. That backdrop fits a story in which dilution and shrinking revenue have outweighed scientific progress.

The bottom line is that Evogene's EPS beat is largely arithmetic: a wider operating loss spread across a much larger share base. Meanwhile, revenue has nearly disappeared following the end of the Bayer agreement. The aGVHD and Septoria programs give the company a more concrete pipeline story than it had a quarter ago. However, with roughly $9 million in cash, rising burn, no new partnerships and a contested boardroom, the investment case now depends on converting that science into a funded collaboration before further dilution erodes shareholder value.

← Back to EVGN news

Read our preview of this report →